Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin. A 52-week, Randomised, Double-blind, Placebo-controlled Trial (PIONEER 8 - Insulin add-on)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Jun 2018
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PIONEER 8
- Sponsors Novo Nordisk
- 08 Dec 2017 Planned End Date changed from 19 Aug 2018 to 23 Aug 2018.
- 08 Dec 2017 Planned primary completion date changed from 14 Jan 2018 to 28 Dec 2017.
- 21 Nov 2017 According to a Novo Nordisk media release, the trial is expected to be completed in 2018.